Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Central serous chorioretinopathy: Towards an evidence-based treatment guideline

Research output: Contribution to journalReviewResearchpeer-review

  1. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options

    Research output: Contribution to journalReviewResearchpeer-review

  2. Inflammation in Glaucoma: From the back to the front of the eye, and beyond

    Research output: Contribution to journalReviewResearchpeer-review

  3. Age-related macular degeneration: A two-level model hypothesis

    Research output: Contribution to journalReviewResearchpeer-review

  4. Optic nerve oxygenation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Branch retinal vein occlusion precipitated by compression between a major retinal artery and underlying optic disc drusen

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cone photoreceptor density in the Copenhagen Child Cohort at age 16-17 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lens fluorescence and skin fluorescence in the Copenhagen Twin Cohort Eye Study: Covariates and heritability

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Thomas J van Rijssen
  • Elon H C van Dijk
  • Suzanne Yzer
  • Kyoko Ohno-Matsui
  • Jan E E Keunen
  • Reinier O Schlingemann
  • Sobha Sivaprasad
  • Giuseppe Querques
  • Susan M Downes
  • Sascha Fauser
  • Carel B Hoyng
  • Felice Cardillo Piccolino
  • Jay K Chhablani
  • Timothy Y Y Lai
  • Andrew J Lotery
  • Michael Larsen
  • Frank G Holz
  • K Bailey Freund
  • Lawrence A Yannuzzi
  • Camiel J F Boon
View graph of relations

Central serous chorioretinopathy (CSC) is a common cause of central vision loss, primarily affecting men 20-60 years of age. To date, no consensus has been reached regarding the classification of CSC, and a wide variety of interventions have been proposed, reflecting the controversy associated with treating this disease. The recent publication of appropriately powered randomised controlled trials such as the PLACE trial, as well as large retrospective, non-randomised treatment studies regarding the treatment of CSC suggest the feasibility of a more evidence-based approach when considering treatment options. The aim of this review is to provide a comprehensive overview of the current rationale and evidence with respect to the variety of interventions available for treating CSC, including pharmacology, laser treatment, and photodynamic therapy. In addition, we describe the complexity of CSC, the challenges associated with treating CSC, and currently ongoing studies. Many treatment strategies such as photodynamic therapy using verteporfin, oral mineralocorticoid antagonists, and micropulse laser treatment have been reported as being effective. Currently, however, the available evidence suggests that half-dose (or half-fluence) photodynamic therapy should be the treatment of choice in chronic CSC, whereas observation may be the preferred approach in acute CSC. Nevertheless, exceptions can be considered based upon patient-specific characteristics.

Original languageEnglish
JournalProgress in Retinal and Eye Research
Volume73
Pages (from-to)100770
ISSN1350-9462
DOIs
Publication statusPublished - Nov 2019

ID: 59235089